May 28, 2026 4:01 pm EDT Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026 7:00 am EDT Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
May 12, 2026 7:00 am EDT Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
May 7, 2026 4:30 pm EDT Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
May 7, 2026 7:00 am EDT Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 4, 2026 4:30 pm EDT Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Apr 10, 2026 6:59 am EDT Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Apr 6, 2026 7:00 am EDT Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital